VEGFA and medulloblastoma: Our results from a gene expression analysis of 423 medulloblastomas further demonstrates enhanced expression of VEGFA in Group 3 compared to other medulloblastoma subgroups, indicating that this patient group in particular may benefit from VEGF-targeted therapies.